People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Senti Biosciences, Inc. | — | Biotechnology | Series B | $77.0M | $222.0M | 2024 |
Kanya Rajangam at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kanya Rajangam on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Alex Kolicich | 1 | 8 |
| James Collins | 1 | 8 |
| Philip Lee | 1 | 4 |
| Donald Tang | 1 | 2 |
| Timothy Lu | 1 | 2 |
| Yvonne Li | 1 | 1 |
| Brenda Cooperstone | 1 | 1 |
| Fran Schulz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.